Baseline data by area of residence
| Suburban patients | Inner city patients | |||||
|---|---|---|---|---|---|---|
| Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | |||
| n | 40 unless stated | 74 unless stated | ||||
| Male | 16 (40%) | 26 (35%) | ||||
| Age | 45 (12) | 49 (33–54) | 42 (12) | 44 (32–52) | ||
| FEV1 (l) | 2.3 (0.8) | 2.3 (1.9–2.8) (n=36) | 2.2 (0.9) | 2.1 (1.4–2.7) (n=73) | ||
| Predicted FEV1 (l) | 3.0 (0.6) | 3.0 (2.4–3.4) | 3.0 (0.6) | 3.0 (2.6–3.4) (n=69) | ||
| PEF (l/min) | 363 (117) | 371 (305–426) (n=36) | 348 (131) | 342 (254–436) (n=73) | ||
| AQLQ total score | 5.1 (0.9) | 5.1 (4.7–5.8) | 4.5 (1.3) | 4.7 (3.5–5.7) | ||
| AQLQ symptom score | 5.2 (1.2) | 5.2 (4.6–6.2) | 4.4 (1.5) | 4.5 (3.1–5.4) | ||
| Q score | 2.2 (1.8) | 2 (1–3) | 3.0 (2.7) | 3 (1–5) | ||
| HAD anxiety | 6.2 (3.9) | 6 (3–8) | 9.5 (4.1) | 9 (7–13) (n=73) | ||
| HAD depression | 3.7 (2.7) | 3 (2–6) | 6.0 (4.3) | 5 (2–9) (n=73) | ||
| Still smoking | 4 (10%) | 27 (36%) | ||||
| BTS guidelines treatment | ||||||
| Step 1 | 9 (23%) | 12(16%) | ||||
| Step 2 | 17 (42%) | 42 (57%) | ||||
| Step 3 | 9 (23%) | 13 (8%) | ||||
| Step 4 | 3 (7%) | 3 (4%) | ||||
| Step 5 | 2 (5%) | 4 (5%) | ||||
IQR = interquartile range; FEV1 = forced expiratory volume in one second; PEF = peak expiratory flow; AQLQ = Asthma Quality of Life questionnaire; HAD = Hospital Anxiety and Depression scale.
BTS guidelines treatment step: step 1 = no β agonist or β agonist prn; step 2 = β agonist prn plus low dose steroids; step 3 β agonist prn plus high dose inhaled steroids or low dose inhaled steroids plus long acting β agonist; step 4 = high dose inhaled steroids and regular β agonist; step 5 = addition of regular steroid tablets.